Eledon Pharmaceuticals, Inc.

Greetings and welcome to the Elladon Pharmaceuticals first quarter financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded today, May 12, 2022. I would now like to turn the conference call over to Paul Little, Chief Financial Officer of Elladon. Please go ahead.

Good afternoon, everyone, and thank you for joining Elladon's first quarter 2022 Operating and Financial Results Conference Call. I'm joined on today's call by David Alexander Groh, Chief Executive Officer, Steve Perrin, President and Chief Scientific Officer, and Jeff Bornstein, Chief Medical Officer. Earlier today, Elladon issued a press release announcing financial results for the first quarter ended March 31st, 2022. You may access the release under the Investors tab on our company's website at elladon.com. I would like to remind everyone that statements made during this conference call relating to Elladon's expected future performance, future business prospects, or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts due to the impact of many factors beyond the control of Elladon. Elladon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Elladon's reports filed with the U.S. Securities and Exchange Commission. Now I would like to pass the call to Elladon CEO, Dr. David Alexander Groh, DA.

Thank you, Paul, and thank you all for joining the call today. We made important progress during the first quarter of 2022 and look forward to continuing this momentum through the remainder of the year. Our priority this year has been and remains executing on our four clinical trials in three therapeutic areas, neurodegeneration focusing on ALS, transplantation focusing on kidney and islet cell transplantation for type 1 diabetes, and autoimmunity focusing on IgA nephropathy or IGAN. Before I turn the call over to Steve to discuss our clinical development pipeline, I would like to provide a brief recap on our recent progress. In our Phase IIa study of togoprobar in adults with ALS, we completed dosing and visits for all subjects enrolled and remain on track to report topline data from this study this quarter. In our Phase IIa study in togoprobar in adults with IGAN, We recently announced that we have begun dosing patients. We have regulatory approval for clinical trial sites in five countries with plans to expand to additional countries, and we are therefore on track to have six-month data available later this year. In transplantation, we now have active sites for kidney transplantation in Canada and the United Kingdom, have an open Canadian site for islet cell transplantation and are preparing to open up a U.S. site for islet cell transplantation in the middle of the year. Similar to our Argonne trial, we plan to communicate our available transplant data at the end of the year. Finally, we recently published a meta-analysis demonstrating the benefits of targeting anti-CD40 ligand as opposed to targeting anti-CD40 receptor in non-human primate models of kidney transplantation. The meta-analysis found a median rejection-free survival of 352 days in the anti-CD40 ligand-treated animals versus 131 days in the anti-CD40-treated animals and only six days in the untreated animal control group. Moreover, the median rejection-free survival after cessation of treatment was 230 days in the anti-CD40 ligand-treated animals versus 60 days in anti-CD40 treated group. I'll now turn the call over to Steve Perrin, our President and Chief Scientific Officer, to provide more details on our development programs. Steve?